18F-FDG PET/CT对骨与软组织肿瘤的诊断价值
作者: |
1,2唐光,
1陈飞
1 中南大学湘雅二医院脊柱外科,长沙 410000 2 湘南学院附属医院脊柱外科,湖南 郴州 423000 |
通讯: |
陈飞
Email: chenfei1972@csu.edu.cn |
DOI: | 10.3978/j.issn.2095-6959.2022.07.012 |
基金: | 郴州市技术创新引导项目(lcyl2021099)。 |
摘要
Diagnostic value of 18F-FDG PET/CT in bone and soft tissue tumors
CorrespondingAuthor: CHEN Fei Email: chenfei1972@csu.edu.cn
DOI: 10.3978/j.issn.2095-6959.2022.07.012
Foundation: This work was supported by Chenzhou Technological Innovation Guidance Project, China (lcyl2021099).
Abstract
Objective: To evaluate the value of 18F-fluorodeoxyglucose (18F-FDG) in the diagnosis and treatment of bone and soft tissue tumors, and to provide a new clinical basis by using glucose metabolism parameters. Methods: The clinical and imaging data of 57 patients with bone and soft tissue tumors or inflammatory changes confirmed by pathology and by positron emission tomography/computed tomography (PET/CT) in the Second Xiangya Hospital of Central South University and the Affiliated Hospital of Xiangnan University from August 2013 to October 2021 were analyzed retrospectively. Results: FDG was positive in mesenchymal malignant tumors, solitary plasmacytomas, bone metastases, and inflammatory lesions. There was significant difference in MTV and TLG between mesenchymal bone tumors and inflammatory lesions. Conclusion: 18F-FDG PET/CT has high value in the early diagnosis of bone and soft tissue tumors by using metabolic parameters such as MTV and TLG.